Fibromyalgia Syndrome is also known as FM or FMS. Fibromyalgia is technically classified as a musculoskeletal disorder, but the condition is now 
The intensity of typical fibromyalgia symptoms varies from person to person and may be influenced by factors such as time of day or weather conditions. Because FMS is a persistent condition, the majority of fibromyalgia symptoms may never vanish unless treated.
Fibromyalgia clinical trials and research have shown that most victims display pain in certain areas. In contrast, others may experience generalized discomfort, including muscle and tendon pain, similar to that observed in some patients with multiple sclerosis.
Other symptoms of Fibromyalgia include:
Stem cells are considered the building blocks of life due to their remarkable potential and natural tendency to regenerate our bodies after injury. They are essentially the body’s pharmacy.
In distress, our bodies release a naturally occurring protein called SDF-1. This protein guides the movement of surrounding cells to initiate homing and help begin the healing process. This “homing” function enables your body’s newly introduced stem cells to travel to the appropriate areas for repair. Autologous (From Your Body) or Allogeneic (HLA-matched and Donated) stem cells are typically isolated from peripheral blood, cord tissue, placental tissue, bone marrow, or adipose fat.[1]
The cells are then processed and expanded in our single-system GMP-approved Class 5 Biomedical clean rooms, where our microbiologists can prepare your therapeutic doses of stem cells.[2]
The prepared UC-MSC-enriched stem cells and neurogenic growth factors are reinjected in multiple stages to promote rapid healing of previously damaged cells.
The ability to extract and expand stem cells for an extended period is unique to our treatments. Expansion or in vitro culturing of stem cells is prohibited in some countries, but is essential for managing FMS symptoms.[3]
The total number of stem cell infusions for FMS and CF will vary based on the patient’s needs.
Types of Cells Used for Fibromyalgia Treatment Protocol: Enriched UC-MSC+ Stem cells do not require any invasive surgeries to harvest seed cells, and the multi-stage cell infusions are usually made via intravenous Drips, Intrathecal delivery, or fluoroscopic guided delivery (hospital setting) might be necessary in some cases to bypass the blood-brain barrier. [4]
Post-Treatment Rehab—Optional: Physical Rehabilitation is typically not required unless patients have other underlying physical issues. However, we offer complete physical rehabilitation services post-therapy in Bangkok. Our rehabilitation team can assist you upon request for 2-5 hours per day, up to 6 days per week. Medical travel visa assistance and extended hotel or apartment accommodations for the patient and family can also be provided upon request.
Our multi-stage treatment for Fibromyalgia with Stem Cells will require 10-14 days in Bangkok, depending on the patient’s needs. Given the varying degrees, locations, and causes of injuries, our rheumatologist and medical team will need to understand a potential patient better before acceptance. Upon completion of the evaluation, a detailed treatment plan will be provided, including specific medical recommendations, a day-by-day calendar with stages, the exact total number of nights required, and the total medical-related costs (excluding accommodations or flights). To begin the qualification process for our multi-stage treatment protocol, please prepare your recent medical records, including blood and urine test results, and contact us.
[1] ^ Yeephu, Suwimon, Chuthamanee Suthisisang, Saithip Suttiruksa, Pradit Prateepavanich, Patchara Limampai, and Irwin Jon Russell. 2013. Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study in Thailand. The Annals of pharmacotherapy, no. 7-8 (June 4). doi:10.1345/aph.1R725. https://www.ncbi.nlm.nih.gov/pubmed/23737510
[2] ^ Gunduz, B, Y A Bayazit, F Celenk, C Saridoğan, A G Guclu, E Orcan, and J Meray. 2008. Absence of contralateral suppression of transiently evoked otoacoustic emissions in fibromyalgia syndrome. The Journal of laryngology and otology, no. 10 (March 4). doi:10.1017/S0022215107001569. https://www.ncbi.nlm.nih.gov/pubmed/18318918
[3] ^ Busse, Jason W, Shanil Ebrahim, Gaelan Connell, Eric A Coomes, Paul Bruno, Keshena Malik, David Torrance, et al. 2013. Systematic review and network meta-analysis of interventions for fibromyalgia: a protocol. Systematic reviews (March 13). doi:10.1186/2046-4053-2-18. https://www.ncbi.nlm.nih.gov/pubmed/23497523
[4] ^ Üçeyler, Nurcan, Daniel Zeller, Ann-Kathrin Kahn, Susanne Kewenig, Sarah Kittel-Schneider, Annina Schmid, Jordi Casanova-Molla, Karlheinz Reiners, and Claudia Sommer. 2013. Small fibre pathology in patients with fibromyalgia syndrome. Brain : a journal of neurology, no. Pt 6 (March 9). doi:10.1093/brain/awt053. https://www.ncbi.nlm.nih.gov/pubmed/23474848